JP2022540921A5 - - Google Patents
Info
- Publication number
- JP2022540921A5 JP2022540921A5 JP2022502559A JP2022502559A JP2022540921A5 JP 2022540921 A5 JP2022540921 A5 JP 2022540921A5 JP 2022502559 A JP2022502559 A JP 2022502559A JP 2022502559 A JP2022502559 A JP 2022502559A JP 2022540921 A5 JP2022540921 A5 JP 2022540921A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- subject
- compound
- treating
- mutation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962874474P | 2019-07-15 | 2019-07-15 | |
| US62/874,474 | 2019-07-15 | ||
| PCT/US2020/042162 WO2021011674A1 (en) | 2019-07-15 | 2020-07-15 | Methods useful in treating cancers harboring a kras or hras mutation or amplification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022540921A JP2022540921A (ja) | 2022-09-20 |
| JP2022540921A5 true JP2022540921A5 (https=) | 2023-07-26 |
Family
ID=74211326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502559A Pending JP2022540921A (ja) | 2019-07-15 | 2020-07-15 | Ｋｒａｓまたはｈｒａｓ変異若しくは増幅を有するがんを処置する際に有用な方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220257599A1 (https=) |
| EP (1) | EP3999049A4 (https=) |
| JP (1) | JP2022540921A (https=) |
| CN (1) | CN114364377A (https=) |
| AU (1) | AU2020315388A1 (https=) |
| CA (1) | CA3147588A1 (https=) |
| WO (1) | WO2021011674A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102679204B1 (ko) * | 2021-02-10 | 2024-06-27 | 한국생명공학연구원 | GPX4 저해제 및 Lp-PLA2 저해제를 포함하는 암 예방 또는 치료용 조성물 |
| WO2024077085A1 (en) * | 2022-10-07 | 2024-04-11 | Memorial Sloan-Kettering Cancer Center | Targeting phospholipase a2 (pla2) in cancer |
| US12314787B2 (en) | 2023-04-27 | 2025-05-27 | Hewlett Packard Enterprise Development Lp | Serving application programming interface calls directed to hierarchical data format files stored in fabric-attached memories |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150017671A1 (en) * | 2004-04-16 | 2015-01-15 | Yaping Shou | Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity |
| CA2830958A1 (en) * | 2011-04-06 | 2012-10-11 | The Scripps Research Institute | N1- and n2-carbamoyl-1,2,3-triazole serine hydrolase inhibitors and methods |
| CN102166364A (zh) * | 2011-04-14 | 2011-08-31 | 江南大学 | 用于治疗卵巢癌的钙离子非依赖性磷脂酶a2的抑制剂 |
| KR20160117596A (ko) * | 2014-02-07 | 2016-10-10 | 오스펙스 파마슈티칼스, 인코포레이티드 | 신규 제약 제제 |
| AU2017329090B9 (en) * | 2016-09-19 | 2019-09-05 | Novartis Ag | Therapeutic combinations comprising a RAF inhibitor and a ERK inhibitor |
| US20190142835A1 (en) * | 2017-11-14 | 2019-05-16 | Oregon Health & Science University | Inhibition of autophagy using phospholipase a2 inhibitors |
-
2020
- 2020-07-15 AU AU2020315388A patent/AU2020315388A1/en not_active Abandoned
- 2020-07-15 JP JP2022502559A patent/JP2022540921A/ja active Pending
- 2020-07-15 US US17/626,370 patent/US20220257599A1/en not_active Abandoned
- 2020-07-15 CN CN202080063214.7A patent/CN114364377A/zh active Pending
- 2020-07-15 CA CA3147588A patent/CA3147588A1/en active Pending
- 2020-07-15 EP EP20841099.3A patent/EP3999049A4/en not_active Withdrawn
- 2020-07-15 WO PCT/US2020/042162 patent/WO2021011674A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022540921A5 (https=) | ||
| Naqvi et al. | Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia | |
| Asilian et al. | Evaluation of CO2 laser efficacy in the treatment of cutaneous leishmaniasis | |
| Yang et al. | Effects of ALA-PDT on the healing of mouse skin wounds infected with Pseudomonas aeruginosa and its related mechanisms | |
| Lee et al. | Effects of interferon‐α2b on keloid treatment with triamcinolone acetonide intralesional injection | |
| Kalokasidis et al. | The effect of Q‐switched Nd: YAG 1064 nm/532 nm laser in the treatment of onychomycosis in vivo | |
| JPWO2021132592A5 (https=) | ||
| Zorzi et al. | A phase I study of histone deacetylase inhibitor, pracinostat (SB939), in pediatric patients with refractory solid tumors: IND203 a trial of the NCIC IND program/C17 pediatric phase I consortium | |
| ATE499934T1 (de) | Verwendung von (3.2.0) heterocyclischen verbindungen und ihren analoga zur behandlung von krebs | |
| Zhang et al. | Development of tumor-evolution-targeted anticancer therapeutic nanomedicineEVT | |
| Arenbergerova et al. | Effective long‐term control of refractory hidradenitis suppurativa with adalimumab after failure of conventional therapy | |
| Jebran et al. | Rapid healing of cutaneous leishmaniasis by high-frequency electrocauterization and hydrogel wound care with or without DAC N-055: a randomized controlled phase IIa trial in Kabul | |
| Gallagher et al. | Alterations in macrophage phenotypes in experimental venous thrombosis | |
| Sápi et al. | Linear state-feedback control synthesis of tumor growth control in antiangiogenic therapy | |
| CN108079303A (zh) | 鞘氨醇激酶抑制剂在制备治疗肝纤维化药物中的应用 | |
| WO2022266302A8 (en) | Systems and methods for improved targeted therapy | |
| Salari-Sharif et al. | Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review | |
| Piretto et al. | How combination therapies shape drug resistance in heterogeneous tumoral populations | |
| Zhu et al. | Theogallin protects myocardial Ischemia-Reperfusion injury by inhibiting the Interleukin-17 signaling pathway | |
| Pastor et al. | In vitro and in vivo antifungal susceptibilities of the Mucoralean fungus Cunninghamella | |
| Bokotas et al. | Wells syndrome: response to dapsone therapy | |
| CN112316149A (zh) | 一种治疗tp53突变的晚期难治性实体瘤的药物及应用 | |
| CN109512822A (zh) | 一种治疗肝癌的联合药物组合物 | |
| TR200501763T2 (tr) | Tedavi ve ilaç tarama yöntemleri | |
| CN119173302A (zh) | 用于应用与个性化超分割立体定向适应性放射疗法相组合的肿瘤治疗电场的方法和仪器 |